Skip to content
InSilens, Biotech Intelligence
Login
  • Home
  • Signals
  • Contact us
  • Subscribe
Explore the platform
InSilens, Biotech Intelligence
INSILENS, A Noetera Company

Biotech Intelligence Platform

Turn Global Biotech Signals, Into Strategic Intelligence

Explore with us

Biotech Signals. Structured for Decisions.

INSILENS converts global biotech activity into decision-grade intelligence for investors, executives, and business development teams.

Deals and Financing
Ultrasound Genetic Medicine Platform Advances Toward Clinic
June 10, 2026
GSK Acquires Nuvalent for $10.6B
June 9, 2026
Incyte Acquires Vega Therapeutics
June 8, 2026
Nurix + Roche; Global BTK Degrader Collaboration
June 8, 2026
Therapeutic Indication
Real-World Validation of Menin Inhibition in Acute Leukemia
June 11, 2026
Rare Hematology Portfolio Real-World Evidence Update
June 11, 2026
First Potential FDA-Approved Therapy for wAIHA
June 11, 2026
Climb Bio Budoprutug Phase 1b, First Anti-CD19 Antibody in ITP
June 11, 2026
Technology Modalities
Parabilis IPO Expansion
June 9, 2026
Regeneron – Gene Therapy Approved for Hearing Loss
April 24, 2026
Cartherics – CAR-NK Manufacturing Expansion
April 15, 2026
Life Biosciences – $80M Gene Therapy Financing
April 9, 2026
View all

Weekly Market Insight

Nurix + Roche; Global BTK Degrader Collaboration
Merck – $1B Google AI Deal
Incyte Acquires Vega Therapeutics
Regeneron – MFN Drug Pricing Agreement
    • Home page
    • Signals
    • Contact us
    • Subscribe

 

  • Deals and Financing
  • Therapeutic Indication
  • Technology Modalities

Contact Us

Need help or have a question?
Contact us at: info@insilens.com

  • Privacy Policy
  • Terms & Conditions

 

Our company

InSilens is a biotech intelligence platform transforming global signals into actionable insights for investors, researchers, and industry leaders. A product of Noetera.

© 2026 InSilens. All rights reserved. A Noetera Company